YONGIN,
First-Quarter Reported Results(1)
Q1 2020 | Growth(2) | |
Total revenues | +8.6% | |
Operating profit | +283.9% | |
K-IFRS profit after taxation | - |
(1) Results from continuing operations (Green Cross MS' blood bag business has been classified as discontinued operations) |
(2) Results and percentages compare to equivalent 2019 period |
Financial Highlights
- Delivered total revenue growth of 8.6%
KRW 307.8 billion (2019 Q1: 283.3 billion), and operation profit increased 238.9% toKRW 6.1 billion (2019 Q1: 1.6 billion) in the first quarter. - Unconsolidated revenues increased 8.1%, reflecting strong international sales.
- Double-digit growth in consolidated subsidiaries, including Green Cross MS and Green Cross LabCell.
- Green Cross local sales up 5.5% reflecting strong CHC segment performance.
- Green Cross international sales benefited from strong vaccines growth, Flu Vx and VZ Vx sales up 711%, 1,095% respectively.
- Operating profit growth driven by favourable mix and bottom line reflected anticipated headwinds.
About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in
This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma's management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
View original content:http://www.prnewswire.com/news-releases/gc-pharma-reports-q1-2020-results-301049139.html
SOURCE GC Pharma
© Canada Newswire, source